curacle co.,ltd. (KOSDAQ:365270)

South Korea flag South Korea · Delayed Price · Currency is KRW
8,850.00
+30.00 (0.34%)
At close: Jul 16, 2026
Market Cap177.46B +150.3%
Revenue (ttm)1.06B -6.8%
Net Income-17.13B
EPS-947.23
Shares Out 21.30M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume62,729
Open8,690.00
Previous Close8,820.00
Day's Range8,500.00 - 8,990.00
52-Week Range3,600.00 - 20,750.00
Beta2.06
Analystsn/a
Price Targetn/a
Earnings Daten/a

About curacle co.,ltd.

curacle co.,ltd., a bio-venture business, engages in the research and development of drugs for intractable vascular and metabolic diseases due to aging. The company’s products in pipeline include CU06, a next-generation oral therapy, which completed phase 2a clinical trial for the treatment of diabetic macular edema; CU01, which completed Phase 2b clinical trial for Nrf2 activation and inhibition of TGF- β/Smad signaling; MT-101, a fully humanized Tie2 agonist antibody for the treatment of renal diseases; and MT-103, a bispecific antibody combi... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 365270
Full Company Profile

Financial Performance

In 2025, curacle co.,ltd.'s revenue was 7.10 million, a decrease of -99.57% compared to the previous year's 1.63 billion. Losses were -18.11 billion, 21.7% more than in 2024.

Financial Statements